Molecular basis for ligand recognition and receptor activation of the prostaglandin D2 receptor DP1

J Jiuyin Xu (State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences) Y Yanli Wu (State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences) Y Youwei Xu (State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences) Y Yang Li X Xinheng He H Heng Zhang J James Jiqi Wang (Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiologic Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) J Jingjing Hou (State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences) J Junrui Li (The Gene and Linda Voiland School of Chemical Engineering and Bioengineering) W Wen Hu (State Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences) K Kai Wu (BNLMS, College of Chemistry and Molecular Engineering) Q Qingning Yuan C Canrong Wu H H. Eric Xu

Abstract

The prostaglandin D2 receptor 1 (DP1), a rhodopsin-like Class A GPCR, orchestrates critical physiological and pathological processes, ranging from sleep regulation to inflammatory responses and cardiovascular function. Despite its therapeutic significance, structural insights into DP1 activation mechanisms have remained elusive. Here, using cryoelectron microscopy (cryo-EM), we determined high-resolution structures of human DP1 in both inactive and active states, with the latter captured in complex with its endogenous agonist PGD2 or the synthetic agonist BW245C, bound to the stimulatory G protein, Gs. Our structures, coupled with functional and mutagenesis studies, unveiled unique structural features of DP1, including an alternative activation mechanism, ligand-selectivity determinants, and G protein coupling characteristics. These molecular insights provide a rational framework for designing selective DP1-targeted therapeutics, both agonists and antagonists, with enhanced specificity and reduced off-target effects, opening broad avenues for treating DP1-associated disorders.

Article Details

Volume / Issue Vol. 122, Issue 22
Published June 03, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (14)

J

Jiuyin Xu

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Y

Yanli Wu

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Y

Youwei Xu

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Y

Yang Li

X

Xinheng He

H

Heng Zhang

J

James Jiqi Wang

Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiologic Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

J

Jingjing Hou

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

J

Junrui Li

The Gene and Linda Voiland School of Chemical Engineering and Bioengineering

W

Wen Hu

State Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

K

Kai Wu

BNLMS, College of Chemistry and Molecular Engineering

Q

Qingning Yuan

C

Canrong Wu

H

H. Eric Xu